Randomized, open-label, phase three study comparing flutamide and abiraterone in patients with advanced prostate cancer after failure of first combined androgen blockade therapy

Authors
Category Primary study
Registry of TrialsUMIN Clinical Trials Registry
Year 2015
INTERVENTION: Patients assigned to receive flutamide therapy. Patients assigned to receive abiraterone therapy. CONDITION: prostate cancer PRIMARY OUTCOME: Biochemical‐free Survival rate INCLUSION CRITERIA: Advanced prostate cancer patients after failure of first combined androgen blockade therapy. Eastern Cooperative Oncology Group performance status of 0 to 2.
Epistemonikos ID: 44a55b878f97e86541745cf3e1834278ab453870
First added on: Aug 23, 2024